Association of functional genes polymorphisms of key enzymes in the metabolism of biogenic amines with paranoid schizophrenia susceptibility and the influence of these polymorphisms on PANSS results in antipsychotic treatment;Zwia̧zki funkcjonalnych polimorfizmów genów kluczowych enzymów w metabolizmie amin biogennych z wystȩpowaniem schizofrenii paranoidalnej oraz ich wpływ na wyniki w PANSS pod wpływem leczenia przeciwpsychotycznego

Psychiatria Polska

Volumn 40, Issue 5, 2006, Pages 913-923

  Tybura, Piotr ^a,b   Grzywacz, Anna ^a   Syrek, Szymon ^a   Parus, Michał ^a   Samochowiec, Jerzy ^a  

^a Katedra i Klinika Psychiatrii Pomorskiej   (Poland)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Genetics; PANSS; Schizophrenia

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BIOGENIC AMINE; CATECHOL METHYLTRANSFERASE; ENZYME; NEUROLEPTIC AGENT; CARRIER PROTEIN; MEMBRANE PROTEIN;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME METABOLISM; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PARANOID SCHIZOPHRENIA; POLYMERASE CHAIN REACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; VARIABLE NUMBER OF TANDEM REPEAT; ADULT; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; FEMALE; GENETICS; HOSPITALIZATION; MALE; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; QUALITY OF LIFE;

ADULT; ANTIPSYCHOTIC AGENTS; CARRIER PROTEINS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA, PARANOID; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 33751100384     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Frazer A, Winokur A, red. Biologiczne podstawy zaburzeń psychicznych. Warszawa: PZWL; 1982.
2. Thompson PM, Rapoport JL, Cannon TD, Toga AW. Obrazowanie mózgu w różnych fazach schizofrenii: dynamiczne i genetyczne mapy mózgu. Psychiatr. Dypl. 2004; 3: 27-33.
3. Coon H, Jensen S, Holik J, Hoff M, Myles-Worsley M, Reimherr F, Wender P, Waldo M, Freedman R, Leppert M, Byerley W. Genomic scan for genes predisposing to schizophrenia. Am. J. Med. Gen. 1994; 54: 59-71.
4. Williams NM, Rees MI, Holmans P, Norton N, Cardno AG, Jones LA, Murphy KC, Sanders RD, McCarty G, Gray MY, Fenton I, McGuffin P, Owen MJ. A two-stage genome scan for schizophrenia susceptibility genes in 196 affected sibling pairs. Hum. Molec. Gen. 1999; 8(9). 1729-1739.
5. Owen MJ, Williams NM, O'Donowan MC: The molecular genetics of schizophrenia: new findings promise new insights. Mol. Psychiatry 2004; 9, 14-27.
6. McGuffin P, Owen MJ, Farmer AE: Genetic basis of schizophrenia. Lancet 1995; 346: 678-682.
7. Hauser J, Kapelski P, Czerski P, Godlewski S, Dmitrzak-Wȩglarz M, Twardowska K, Rybakowski J. Brak asocjacji pomiȩdzy polimorfizmem VNTR genu DAT a schizofrenia̧. Psychiatr. Pol. 2002; 3: 413-419.
8. Grossman MH, Emanuel BS, Budarf ML. Chromosomal mapping of human calecholamine-o-methyltransferase gene to 22q11.1-q11.2. Genom. 1992; 12: 822-825.
9. Dunham I, Collins J, Wadey R, Scambler P. Possible role for COMT in psychosis associated with velo-cardio-facial syndrome. Lancet 1992; 340: 1361-1362.
10. Lotta T, Vidgren J, Tilgmann C, Umanen I, Melen K, Julkunen I. Kinetics of human soluble and membrane bound catechol-o-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochem. 1995; 34: 4202-4210.
11. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum R. Human catechol-o-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogen. 1996; 6: 243-250.
12. Chen Z-Y, Powell JF, Hsu Y-PP, Breakefield XO, Craig IW. Organization of the human monoamine oxidase genes and long-range physical mapping around them. Genom. 1992; 14: 75-82.
13. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Gen. 1998; 103: 237-279.
14. World Health Organisation: International statistical classyfication of diseases and health related problems - tenth revision. WHO Collaborating Centre for Research and Training in Mental Health, 1993.
15. Robins LE, Wing J, Wittchen HU, Heizer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Riegier DA. The Composite International Diagnostic Interview: an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch. Gen. Psychiatry 1988; 45: 1069-1077.
16. Kay SR, Fiszbein A, Opler L. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13/2: 261-276.
17. Miller S, Dykes D, Plesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl. Acids Res. 1988; 16: 1215.
18. Statistical package for social sciences. Version 4.01, SSPS-Inc. München; 1991.
19. Palmatier MA, Kang AM, Kid KK. Different catechol-o-methyltransferase alleles. Biol. Psychiatry 1999; 46: 557-567.
20. Daniels JK, Williams NM, Williams J, Jones LA, Cardno AG, Murphy KC, Spurlock G, Riley B, Scamber P. Asherson P, McGuffin P, Owen MJ. No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol-o-methyltransferase activity. Am. J. Psychiatry 1996; 153: 2, s. 268-270.
21. Karayiorgou M, Gogos JA, Galke BL, Wolyniec PS, Nestad G, Antonarakis SE, Kazazian HH, Housman DE, Pulver AE. Identification of sequence variant and analysis of the role of the catechol-o-methyltransferase gene in schizophrenia susceptibility. Biol. Psychiatry 1998; 43: 425-431.
22. Li T, Sham PC, Vallada H, Xie T, Tang X, Murray RM, Liu X, Collier DA. Preferential transmission of the high activity allele of COMT in schizophrenia. Psychiatr. Gen. 1996; 6: 131-133.
23. Kunugi H, Vallada HP, Sham PC, Hoda F, Arranz MJ, Li T, Nanko S, Murray RM, McGuffin P, Owen M, Gill M, Collier DA. Catechol-o-methyltransferase polymorphisms and schiophrenia: transmission disequilibrium study in multiply affected families. Psychiatr. Gen. 1997; 7: 97-101.
24. Ohmori O, Shinkai T, Kojima H, Terao T, Suzuki T, Mita T, Abe K. Association study of functional catechol-o-methyltransferase gene polymorphism in Japanese schizophrenics. Neurosc. Lett. 1998; 243: 109-112.
25. Wei J, Hemmings GP. Lack of evidence for association between the COMT locus and schizophrenia. Psychiatr. Gen. 1999; 9: 183-186.
26. Jin BF, Chang SZ, Niu FG, Xing WL, Wei WS, Hong YW, Guo YF, David SC, Lin H. Catechol-o-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis. Biol. Psychiatry 2005; 2: 139-144.
27. Munafo MR, Bowes L, Clark TG, Flint J. Lack of association of the COMT (Val 158/108 Met) gene and schizophrenia: meta-analysis of case-control studies. Molec. Psychiatry 2005; 10: 765-770.
28. Bray NJ, Buckland PR, Williams NM, Williams HJ, Norton N, Owen MJ. A haplotype implicated in schizophrenia human brain. Am. J. Hum. Gen. 2003; 73: 152-161.
29. Herken H, Erdal ME. Catechol-o-methyltransferase gene polymorphism in symptomatology and prognosis. Psychiatr. Gen. 2001; 11: 105-109.
30. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molec. Psychiatry 2004; 9: 442-473.
31. Sasaki T, Hattori M, Sakai T, Kato T, Kunugi H, Hirose T, Nanko S. The monoamine oxidase A gene and major psychosis in Japanese subjects. Biol. Psychiatry 1998; 9: 922-924.
32. Coron B, Campion D, Thibaut F, Dolfus S, Preterre P, Langlois S, Vasse T, Moreau V, Martin C, Charbonnier F, Laurent C, Mallet J, Petit M, Frebourg T. Association study between schizophrenia and monoamine oxidase A and B DNA polymorphisms. Psychiatry Res. 1996; 3: 221-226.
33. DeLisi LE, Wise CD, Potkin SG, Zalcman S, Phelps BH, Lovenberg W, Wyat RJ. Dopamine-beta-hydroxylase, monoamino oxydase, and schizophrenia. Biol. Psychiatry 1980; 6: 895-907.
34. Norton N, Kirov G, Zammit S, Jones G, Jones S, Owen R, Krawczak M, Wiliams NM, O'Donowan MC, Owem MJ. Schizophrenia and functional polymorphisms in the MAOA and COMT genes: No evidence for association or epistasis. Am. J. Med. Genet. 2002; 5: 491-496.
35. Syagailo YV, Stober G, Grassle M, Reimer E, Knapp M, Jangkunz G, Okladnowa O, Meyer J, Lesch KP. Association analysis of the functional monoamine oxidase A gene promoter polymorphism in the psychiatric disorders. Am. J. Med. Genet. 2001; 2: 168-171.